drug, Duovir-N, a fixed dose combination o f 3 drugs, Zidovudine, Lamivudine and Nevirapine and thereafter its ACT, Lumartem

which consists of Artemether and After its comm issioning, the facility underwent an intensive validation phase aimed at ensurin g that all equipments and systems that were installed met the required standards of Good Manufacturing Practice. This took up the better time of 2008 and culmin ated in receipt of various regulatory approvals from National Drug Authority (ND A), Drugs for neglected diseases(DNDI) and ICRC (International committee for Red cross), Geneva In 2009 QCIL began its maiden production, commencing with its Antiretroviral dru g, Duovir-N, a fixed dose combination of 3 drugs, Zidovudine, Lamivudine and Nev irapine and thereafter its ACT, Lumartem which consists of Artemether and